Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022006184 - CELLULAR ENERGY INHIBITOR FORMULATIONS FOR THE TREATMENT OF PATHOGENIC INFECTIONS AND ASSOCIATED METHODS

Publication Number WO/2022/006184
Publication Date 06.01.2022
International Application No. PCT/US2021/039722
International Filing Date 29.06.2021
IPC
A61P 31/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
A61P 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C07C 59/185 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
59Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O-metal, -CHO, keto, ether, groups, groups, or groups
185Saturated compounds having only one carboxyl group and containing keto groups
C07C 59/19 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
59Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O-metal, -CHO, keto, ether, groups, groups, or groups
185Saturated compounds having only one carboxyl group and containing keto groups
19Pyruvic acid
CPC
A61K 31/137
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine ; or methadone
A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
A61K 31/7004
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7004Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7012
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61K 38/005
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
005Enzyme inhibitors
A61K 38/45
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
45Transferases (2)
Applicants
  • KODISCOVERY, LLC [US]/[US]
Inventors
  • KO, Young Hee
Agents
  • ALDER, Todd, B.
Priority Data
62/705,47529.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CELLULAR ENERGY INHIBITOR FORMULATIONS FOR THE TREATMENT OF PATHOGENIC INFECTIONS AND ASSOCIATED METHODS
(FR) FORMULATIONS D'INHIBITEUR D'ÉNERGIE CELLULAIRE POUR LE TRAITEMENT D'INFECTIONS PATHOGÉNIQUES ET PROCÉDÉS ASSOCIÉS
Abstract
(EN) Compositions and methods for protecting a subject against, or treating a subject with, a pathogenic infection are presented. A method includes administering a composition including a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR', N(R")2, C(O)R''', C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R' represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R''', R'' represents H, C1-C6 alkyl, or C6-C12 aryl, and R''' represents H, C1-C20 alkyl or C6-C12 aryl, at least one sugar to stabilize the cellular energy inhibitor and a biological buffer present in an amount sufficient to at least partially deacidify the cellular energy inhibitor and neutralize metabolic by-products of the cellular energy inhibitor.
(FR) Compositions et méthodes destinées à protéger un sujet contre une infection pathogène ou à traiter un sujet en étant atteint. Une méthode comprend l'administration d'une composition comprenant un inhibiteur d'énergie cellulaire présentant la structure représentée par la formule I, dans laquelle X est choisi dans le groupe constitué par : un nitro, un imidazole, un halogénure, un sulfonate, un carboxylate, un alcoxyde et un oxyde d'amine; et R est choisi dans le groupe constitué par : OR', N(R")2, C(O)R''', alkyle en C1-C6, aryle en C6-C12, hétéroalkyle en C1-C6, hétéroaryle en C6-C12, H, et un métal alcalin; où R' représente H, un métal alcalin, alkyle en C1-C6, aryle en C6-C12 ou C(O)R''', R'' représente H, alkyle en C1-C6 ou aryle en C6-C12, et R''' représente H, alkyle en C1-C20 ou aryle en C6-C12, au moins un sucre pour stabiliser l'inhibiteur d'énergie cellulaire ainsi qu'un tampon biologique présent en une quantité suffisante pour désacidifier au moins partiellement l'inhibiteur d'énergie cellulaire et neutraliser des sous-produits métaboliques de l'inhibiteur d'énergie cellulaire.
Latest bibliographic data on file with the International Bureau